The only dose on record for bioglutide comes from clinical trials, not from community protocols. In the Phase 2 study (NCT06564753), the trial used a once-daily oral dose, and the top arm at 150 mg/day produced 13.8% mean weight loss over 13 weeks, per the conference reporting. There is no established research-use or self-dosing information for bioglutide yet, because it hasn't reached the research market in any vetted, established way.
Bioglutide (NA-931) also differs from every injectable agonist in this space in a way that changes what "dosing" even means: it is an oral small molecule, taken by mouth once daily, and the trial reported food-independent pharmacokinetics. There is nothing to reconstitute, no bacteriostatic water, and no syringe conversion. This guide reports the dose the trials used, the pharmacokinetic profile the trial described, and why no self-dosing protocol exists yet.
Research-context information only. Bioglutide (NA-931) is an investigational drug not approved by the FDA. Protocols, doses, and reactions reported below come from published clinical trials and self-reported community sources. This article reports what has been documented, not what should be done. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. Consult a licensed physician for personal medical decisions.
Bioglutide is described as a quadruple agonist — a single oral molecule engineered to activate four pathways: IGF-1, GLP-1, GIP, and glucagon. Three of those are the incretin-and-glucagon axis that retatrutide already targets; the fourth, IGF-1, is the muscle-preservation angle the trial data emphasizes. Below: the trial dose, the oral pharmacokinetics, and the honest state of dosing information for a compound that is not on the research market.
The Only Dose on Record: What the Trials Used
Every dose figure for bioglutide traces back to its clinical program. There are two data points, both trial-reported:
- Phase 2 (NCT06564753): a once-daily oral dose, with the top arm at 150 mg/day. Over the 13-week, randomized, double-blind, placebo-controlled trial in 125 adults with obesity, the trial reported 13.8% mean weight loss (12.4% placebo-adjusted) at that dose, with a dose-dependent response across arms. These figures were presented at ADA 2025 (late-breaking abstract 2189-LB, in Diabetes), ENDO 2025, and EASD 2025.
- Phase 1 (Endocrine Practice): the earlier first-in-human study reported roughly 10-13% weight loss over 12 weeks, the signal the Phase 2 trial was designed to confirm and extend.
That is the complete public dosing record. The 150 mg/day figure is a trial-administered dose, not a recommendation, and it is conference-reported data rather than a peer-reviewed outcomes paper — the appropriate level of caution for any single-source, conference-stage readout. On tolerability at that dose, the trial reported mostly mild gastrointestinal adverse events (nausea and vomiting at 7.3%, diarrhea at 6.3%), the profile that tracks with the GLP-1 component of the molecule.
Oral, Once-Daily, Food-Independent: Why the PK Is Different
The pharmacokinetic profile is what sets bioglutide apart from the injectable field, and it is the reason a conventional "dosing guide" does not apply. As reported in the trial:
- Oral small molecule. Bioglutide is taken by mouth, not injected. There is no vial, no reconstitution, and no injection technique involved.
- Once daily. The trial dosing schedule was a single daily oral dose, rather than the weekly injections that define the incretin-agonist class.
- Food-independent. The trial reported that blood levels were consistent whether the dose was taken fasted or after a high-fat meal — meaning the trial protocol did not require timing the dose around meals.
Taken together, that removes the entire apparatus most peptide dosing guides are built around: no bacteriostatic-water math, no milligram-to-units syringe conversion, no injection-site rotation, no cold-chain reconstitution steps. For an oral once-daily compound, "how it was dosed" reduces to the trial-administered milligram amount and the once-daily schedule described above.
No Community or Research-Use Dosing Exists Yet
This is the honest state of things: there is no established community or research-use dosing protocol for bioglutide yet, because it hasn't reached the research market in any vetted, established way.
Bioglutide is an investigational drug advancing toward Phase 3. It isn't in our vetted vendor lineup yet, and no established self-experimenter protocols have accumulated the way they do around long-available research peptides — so there's little community material to report. Early gray-market listings are beginning to surface as it gets attention; until a source we've vetted for identity and COA carries it, treat any current listing as unverified and confirm a batch COA before ordering.
If and when bioglutide reaches the research market and self-reported community protocols begin to emerge, this guide will be updated to document them under the usual community-report framing. Until then, the trial-administered 150 mg/day once-daily oral dose is the only figure on record, and it is reported here as trial data — not as a protocol to follow.
Why Oral Changes the Dosing Picture vs Injectables
The injectable triple agonists that dominate this space — retatrutide chief among them — are dosed in weekly subcutaneous milligrams, and their dosing guides are largely reconstitution-and-units math. Bioglutide's oral once-daily route removes that layer entirely, which is the practical convenience the oral format offers against the injectable class.
It also means the numbers do not translate. Bioglutide's 150 mg/day oral figure cannot be lined up against retatrutide's single-digit-milligram weekly injection doses — different route, different frequency, different molecule class, different bioavailability. A milligram of an oral small molecule and a milligram of an injected peptide are not the same quantity of drug reaching circulation. Comparing the two on raw milligrams overstates what can be concluded; the only fair comparison is trial outcome to trial outcome, and those trials were not head-to-head.
For readers tracking the accessible end of this pathway space, retatrutide is the closest analog available from research vendors today — it shares three of bioglutide's four targets (GLP-1, GIP, glucagon), and unlike bioglutide it is actually on the research market with documented community dosing.
